BioSante Pharmaceuticals to Present at 5th Annual Needham & Company Biotechnology & Medical Technology Conference

Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, will present a corporate and clinical overview of the company at the 5th Annual Needham & Company Biotechnology & Medical Technology Conference. The presentation is scheduled for June 14, 2006, at 4:00 p.m. EDT, and will be available as a live audio webcast on http://www.wsw.com/webcast/needham15/bpa/, with a replay available for 90 days.

Key Takeaways:

• BioSante Pharmaceuticals is developing a pipeline of hormone therapy products to treat both men and women, including Bio-E-Gel(R) (transdermal estradiol gel) for menopausal symptoms and LibiGel(R) (transdermal testosterone gel) for female sexual dysfunction (FSD).
• The company submitted a new drug application (NDA) for Bio-E-Gel in the first quarter of 2006.
• The current market for estrogen and testosterone products in the U.S. is approximately $2.5 billion.
• BioSante is also developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including avian flu and biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems.
• The company's lead products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone.
• BioSante's products are licensed by Antares Pharma Inc.

Statistics:

• $2.5 billion: The current market in the U.S. for estrogen and testosterone products.
• 4:00 p.m. EDT: The scheduled time for Stephen M. Simes' presentation at the conference.
• 90 days: The availability of the live audio webcast replay.

Sources:

• BioSante Pharmaceuticals, Inc., Press Release, Date not specified (2006).
• BioSante Pharmaceuticals, Inc., Corporate Website, www.biosantepharma.com.